ADC Landscape
AstraZeneca (KYM/CSPC)
Claudin 18.2 · Gastric / GEJ cancer
Phase 3Antibody–Drug Conjugates
Target
Claudin 18.2
Payload
MMAE
Payload class
Auristatin
Linker
Cleavable
Indication
Gastric / GEJ cancer
Phase
Phase 3
Partner
— (licensed from China)
Overview
Claudin18.2 is the hot gastric-cancer target; AZ's ADC (China-licensed) advancing in Phase 3 against a crowded field of bispecifics and CAR-Ts.
Technology
AstraZeneca (KYM/CSPC) works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.